Process development of ABT-450 – A first generation NS3/4A protease inhibitor for HCV-Reference-Cited by-同舟云学术

Process development of ABT-450 – A first generation NS3/4A protease inhibitor for HCV

Published:2019-08 Issue:32 Volume:75 Page:4271-4286
ISSN:0040-4020
Container-title:Tetrahedron
language:en
Short-container-title:Tetrahedron

Author:

Caspi Daniel D.,Cink Russell D.,Clyne Dean,Diwan Moiz,Engstrom Kenneth M.,Grieme Timothy,Mei Jianzhang,Miller Robert W.,Mitchell Clifford,Napolitano José G.,Nere Nandkishor,Ravn Matthew M.,Sheikh Ahmad,Wagaw Seble,Zhang Hongqiang

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Reference30 articles.

1. Global Hepatitis Report 2017;World Health Organization,2017

2. Management of acute HCV infection in the era of direct-acting antiviral therapy

3. Global distribution and prevalence of hepatitis C virus genotypes

4. Epidemiology and natural history of HCV infection

5. Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroED;Advanced Biology;2024-02-21

2. FDA/M-CERSI Co-Processed API Workshop Proceedings;Journal of Pharmaceutical Sciences;2023-08

3. Catalytic Asymmetric Deoxygenative Cyclopropanation Reactions by a Chiral Salen-Mo Catalyst;Journal of the American Chemical Society;2023-01-10

4. Effect of Vehicle Composition on the Preparation of Different Types of Dapsone Crystals for Topical Drug Delivery;Molecular Pharmaceutics;2022-06-16

5. Large-Scale Amidations in Process Chemistry: Practical Considerations for Reagent Selection and Reaction Execution;Organic Process Research & Development;2022-06-07